Lack of cardioprotection from subcutaneously and preischemic administered liraglutide in a closed chest porcine ischemia reperfusion model
We exclude weight loss, the entire anti-obesity category
CURRENTLY AVAILABLE GLP-1RA BASED THERAPIES FOR OBESITY In 1964, it was discovered that when glucose was administered orally, more insulin was secreted than when it was injected intravenously, confirming the existence of incretin, a gastrointestinal factor that promotes insulin secretion [21]
Based on this finding, two incretin-based medications were developed: (1) DPP-4 inhibitors that increase the concentration of GLP-1 by inhibiting it [22], and (2) GLP-1RAs, which act directly on the GLP-1 receptor [23]
GLP-1 agonists are large peptide molecules
M., DAlessio, D., Grewal, D